This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessArticle
Solid Lipid Nanoparticles Loaded with Dexamethasone Palmitate for Pulmonary Inflammation Treatment by Nebulization Approach
by
Hsin-Hung Chen
Hsin-Hung Chen 1
,
Chen-Hsiang Sang
Chen-Hsiang Sang 2,
Chang-Wei Chou
Chang-Wei Chou 1,
Yi-Ting Lin
Yi-Ting Lin 2,
Yi-Shou Chang
Yi-Shou Chang 1,2 and
Hsin-Cheng Chiu
Hsin-Cheng Chiu 1,*
1
Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan
2
Department of R&D, Medical Division, MicroBase Technology Corp, Taoyuan City 33464, Taiwan
*
Author to whom correspondence should be addressed.
Pharmaceutics 2024, 16(7), 878; https://doi.org/10.3390/pharmaceutics16070878 (registering DOI)
Submission received: 31 May 2024
/
Revised: 25 June 2024
/
Accepted: 27 June 2024
/
Published: 29 June 2024
Abstract
Pneumonia stands as the leading infectious cause of childhood mortality annually, underscoring its significant impact on pediatric health. Although dexamethasone (DXMS) is effective for treating pulmonary inflammation, its therapeutic potential is compromised by systemic side effects and suboptimal carrier systems. To address this issue, the current study introduces solid lipid nanoparticles encapsulating hydrophobic dexamethasone palmitate (DXMS-Pal-SLNs) as an anti-inflammatory nanoplatform to treat pneumonia. The specialized nanoparticle formulation is characterized by high drug loading efficiency, low drug leakage and excellent colloidal stability in particular during nebulization and is proficiently designed to target alveolar macrophages in deep lung regions via local delivery with the nebulization administration. In vitro analyses revealed substantial reductions in the secretions of tumor necrosis factor-α and interleukin-6 from alveolar macrophages, highlighting the potential efficacy of DXMS-Pal-SLNs in alleviating pneumonia-related inflammation. Similarly, in vivo experiments showed a significant reduction in the levels of these cytokines in the lungs of mice experiencing lipopolysaccharide-induced pulmonary inflammation after the administration of DXMS-Pal-SLNs via nebulization. Furthermore, the study demonstrated that DXMS-Pal-SLNs effectively control acute infections without causing pulmonary infiltration or excessive recruitment of immunocytes in lung tissues. These findings highlight the potential of nebulized DXMS-Pal-SLNs as a promising therapeutic strategy for mitigating pneumonia-related inflammations.
Share and Cite
MDPI and ACS Style
Chen, H.-H.; Sang, C.-H.; Chou, C.-W.; Lin, Y.-T.; Chang, Y.-S.; Chiu, H.-C.
Solid Lipid Nanoparticles Loaded with Dexamethasone Palmitate for Pulmonary Inflammation Treatment by Nebulization Approach. Pharmaceutics 2024, 16, 878.
https://doi.org/10.3390/pharmaceutics16070878
AMA Style
Chen H-H, Sang C-H, Chou C-W, Lin Y-T, Chang Y-S, Chiu H-C.
Solid Lipid Nanoparticles Loaded with Dexamethasone Palmitate for Pulmonary Inflammation Treatment by Nebulization Approach. Pharmaceutics. 2024; 16(7):878.
https://doi.org/10.3390/pharmaceutics16070878
Chicago/Turabian Style
Chen, Hsin-Hung, Chen-Hsiang Sang, Chang-Wei Chou, Yi-Ting Lin, Yi-Shou Chang, and Hsin-Cheng Chiu.
2024. "Solid Lipid Nanoparticles Loaded with Dexamethasone Palmitate for Pulmonary Inflammation Treatment by Nebulization Approach" Pharmaceutics 16, no. 7: 878.
https://doi.org/10.3390/pharmaceutics16070878
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.